Example collocations logo

Vaccine in sentence

824 examples of Vaccine in a sentence

They were asked to examine what could be achieved with extra investments in six key areas: prevention of sexual transmission, reduction of non-sexual transmission, treatment of those who have the disease, initiatives to use social policy and health-system strengthening to fight HIV/AIDS, and vaccine research.
Most importantly, they identified an urgent need for increased investment in developing an HIV vaccine.
We also need to introduce counseling to ensure that men do not treat circumcision as a vaccine, and engage in riskier behavior as a result.
WASHINGTON, DC – For those on the frontline of the battle against malaria, news of the development of a vaccine against the parasite is an exciting development.
In July, the European Medicines Agency approved RTS,S – a vaccine also known by its trade name, Mosquirix – for use in children from six weeks to 17 months old.
The global health community has long appreciated the importance of a vaccine in reducing the disease’s burden, and the World Health Organization is expected to make an announcement in November about the use of Mosquirix in countries where malaria is endemic, some 30 excruciating years after researchers at the pharmaceutical company GlaxoSmithKline (GSK) began working on the vaccine.
Many of the people who most need the new vaccine are poor.
Many African governments have shown some willingness to invest in public health infrastructure in the past; but a political commitment to the vaccine could mean redirection of resources from other important tools, including rapid test kits, cheap drugs, safe insecticides, and long-lasting insecticidal bed nets.
It might be asking too much to expect them to pay for the vaccine.
There are also questions about some countries’ capacity to distribute the vaccine, as well as uncertainty about how it will hold up under real-world conditions.
For example, the testing for Mosquirix did not account for the possibility that parents would neglect to use insecticide-treated nets for their children because of a false sense of safety and security provided by the vaccine.
The polio vaccine faced an uphill battle in Nigeria, and the new malaria vaccine could suffer a similar fate.
More recently, skepticism about vaccine safety and efficacy has been on the rise in Southern Europe.
According to a 2016 study, Greece is now among the top ten countries worldwide with the lowest confidence in vaccine safety.
In May, Greece and Italy each enacted very different policies to respond to vaccine skepticism.
Governments should be educating the public to improve overall coverage, not validating unfounded fears about vaccine safety.
Moreover, last year, regulators gave the green light to GSK’s malaria vaccine.
In the early 1980s, one of us almost lost our baby son to bacterial meningitis, because no vaccine was available in Pakistan at the time.
The boy’s siblings were later vaccinated, too, but only after stocks of the vaccine were secured in the US and hand-carried back to Pakistan.
These groups spread falsehoods about vaccine safety that can lead parents to leave their children unprotected.
Finally, we must continue to encourage countries in the region to increase vaccine coverage rates, in particular with newer vaccines proven to protect against pneumonia and diarrhea, the two leading infectious killers of children.
In Pakistan, for example, officials in Punjab province, hoping to protect one million children from a common form of diarrhea, recently introduced the rotavirus vaccine.
The Gates Foundation has sensibly begun to facilitate consultations with leading scientists on accelerating the development of potent new tools, and is already funding the development of a vaccine, as well as new drugs and diagnostics.
As my colleagues at the University of California, San Francisco, have reported, the Sugar Research Foundation – the industry’s trade group – even sought to persuade clinical medicine to focus on saturated fat instead of sugar, and pushed clinical dentistry to focus on a vaccine for tooth decay rather than sugar reduction.
Indeed, there is no vaccine available for any of the three resistance threats that the US Centers for Disease Control and Prevention considers “urgent”: Clostridium difficile, carbapenem-resistant enterobacteriaceae, and drug-resistant Neisseria gonorrhoeae.
And yet a new vaccine remains many years away, especially given that funding for TB vaccine research has declined in recent years.
These deaths are completely preventable – by a jab that is already available in many parts of the world, the pneumococcal conjugate vaccine.
Similarly, the rotavirus vaccine could be used to prevent outbreaks of diarrheal diseases, a chief cause of child mortality in developing countries and a major driver of antibiotic use.
At the World Economic Forum’s annual gathering in Davos last month, 85 companies, including vaccine developers, large pharmaceutical companies, diagnostic developers, and biotech firms, committed to further action to reduce drug resistance.
The most promising answer for the long term is a vaccine to protect against the disease.
BackNext